Suicidality from paroxetine

Paroxetine increases the risk of birth defects in women taking the drug during their first trimester of pregnancy. Evidence from case studies, epidemiological studies, experimental research, and theory supports the view that SSRIs increase suicide risk for some patients. 

Medwar, C., Herxheimer, A. (2003-2004). A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behaviour with paroxetine. International Journal of Risk and Safety in Medicine, 16, 5-19. 

Fluoxetine and other selective serotonin reuptake inhibitors (SSRIs) have been associated with increasing suicidal ideation in some populations of patients. Recent studies have led the British Department of Health to warn physicians against using paroxetine off label. Fluoxetine was specifically exempted from this recommendation. Long-term studies of patients with depression who were treated with fluoxetine have shown it to be fairly well tolerated. Primary adverse effects include nausea (23%), headache (21%), and insomnia (20%). 

Clinical trials have concluded that 2 or 3 of every 100 children and teenagers treated with antidepressants might be at higher risk of suicidal behavior. Data regarding suicidal behavior varies among the antidepressants, whioh leads to the conolusion that no antidepressant is free from risk at this time. Most of the suicides have occurred with the SSRIs, especially paroxetine (Paxil)... 

---